KR101057484B1 - 소장의 조영을 위한 경구용 조영제 - Google Patents
소장의 조영을 위한 경구용 조영제 Download PDFInfo
- Publication number
- KR101057484B1 KR101057484B1 KR1020100024761A KR20100024761A KR101057484B1 KR 101057484 B1 KR101057484 B1 KR 101057484B1 KR 1020100024761 A KR1020100024761 A KR 1020100024761A KR 20100024761 A KR20100024761 A KR 20100024761A KR 101057484 B1 KR101057484 B1 KR 101057484B1
- Authority
- KR
- South Korea
- Prior art keywords
- iron oxide
- microsphere
- contrast
- copolymer
- pcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000813 small intestine Anatomy 0.000 title claims abstract description 26
- 239000002872 contrast media Substances 0.000 title claims abstract description 24
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 98
- 239000004005 microsphere Substances 0.000 claims description 59
- 229920001610 polycaprolactone Polymers 0.000 claims description 59
- 239000000693 micelle Substances 0.000 claims description 53
- 229920001577 copolymer Polymers 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 27
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 17
- 229940031182 nanoparticles iron oxide Drugs 0.000 claims description 17
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000002243 precursor Substances 0.000 claims description 11
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 239000004632 polycaprolactone Substances 0.000 claims description 9
- 239000004814 polyurethane Substances 0.000 claims description 6
- -1 iron oxide ions Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000007762 w/o emulsion Substances 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 235000013980 iron oxide Nutrition 0.000 description 46
- 239000000243 solution Substances 0.000 description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 15
- 229920003134 Eudragit® polymer Polymers 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 229920001400 block copolymer Polymers 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920000249 biocompatible polymer Polymers 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000002616 MRI contrast agent Substances 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229920000359 diblock copolymer Polymers 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920000375 Poly(ethylene glycol)-block-poly(ε−caprolactone) methyl ether Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WQKHTJFZNMYFQC-UHFFFAOYSA-L dichloroiron;hydrate Chemical compound O.Cl[Fe]Cl WQKHTJFZNMYFQC-UHFFFAOYSA-L 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097789 heavy mineral oil Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VITRLXDSBBVNCZ-UHFFFAOYSA-K trichloroiron;hydrate Chemical compound O.Cl[Fe](Cl)Cl VITRLXDSBBVNCZ-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
도 2는 mPEG-PCL와 철 산화물을 포함하는 미셀에서 mPEG-PCL 함량이 높을 수록 마이크로스피어에 포접되는 철 산화물의 양이 많다는 것을 나타낸 모식도이다.
도 3은 메톡시폴리에틸렌-폴리에틸렌글리콜(mPEG-PCL) 블록 공중합체의 1H-NMR 결과를 나타낸 것이다.
도 4는 mPEG-PCL와 철 산화물을 포함하는 미셀에서 생체 적합성 고분자인 mPEG-PCL 함량에 따른 미셀의 입자 크기를 나타낸 것이다.
도 5는 mPEG-PCL와 철 산화물을 포함하는 미셀에서 생체 적합성 고분자인 mPEG-PCL 함량에 따른 T2 자기 이완(T2 relaxation)을 나타낸 것이다.
도 6은 mPEG-PCL와 철 산화물을 포함하는 미셀에서 생체 적합성 고분자인 mPEG-PCL 함량에 따른 TEM을 나타낸 것이다. 도 6에서 (A)는 mPEG-PCL이 Fe3O4 mol수에 비해 0.01배 첨가된 군이고, (B)는 mPEG-PCL이 0.005배 첨가된 군이고, (C)는 mPEG-PCL이 0.001배 첨가된 군이고, (D)는 mPEG-PCL이 0.0005배 첨가된 군이고, (E)는 mPEG-PCL이 첨가되지 않은 군이다.
도 7에서 (A)는 마이크로스피어의 SEM 사진을 500배로 확대한 것이고, (B)는 마이크로스피어의 단면의 SEM 사진을 2000배로 확대한 것이고, (C)는 마이크로스피어 단면에 있는 밝은 색의 스팟에 대한 EDX 분석 결과를 나타낸 것이고, (D)는 마이크로스피어 단면에 있는 어두운 색의 스팟에 대한 EDX 분석 결과를 나타낸 것이다.
도 8은 마이크로스피어에서 철 산화물을 기준으로 mPEG-PCL 함량(X 축)에 따른 철 산화물의 포접 효율(Y 축)을 나타낸 것이다.
도 9는 쥐에 마이크로스피어를 먹인 후 소장을 절개하여 그 단면을 염색한 결과이다. 검은 점으로 보이는 것이 장까지 도달한 조영제이다.
철 산화물:mPEG - PCL = 1:X (몰비) |
철 산화물:mPEG - PCL = 1:X (중량비) |
mPEG-PCL의 함유량 (w/w, %) |
X=0.01 | 0.86 | 46.2 |
X=0.005 | 0.43 | 30.1 |
X=0.001 | 0.086 | 7.9 |
X=0.0005 | 0.043 | 4.1 |
X=0 | 0 | 0 |
mPEG-PCLx Fe3O4:mPEG-PCL =1:x(몰비) |
실제 포접량 (mg) |
이론적인 포접량 (mg) |
포접 효율(%) |
x=0.01 | 1.31±0.31 | 1.08 | 121.90±28.70 |
x=0.005 | 1.25±0.29 | 1.40 | 89.60±20.80 |
x=0.001 | 1.53±0.05 | 1.84 | 82.90±2.55 |
x=0.0005 | 1.28±0.45 | 1.92 | 66.70±23.25 |
x=0 | 0.98±0.02 | 2.00 | 49.18±1.15 |
Claims (12)
- 폴리카프로락톤(PCL), 폴리락트산(poly lactic acid, PLA) 및 폴리우레탄 (poly urethane, PU)으로 이루어진 군으로부터 선택된 소수성 중합체 및 친수성 중합체를 포함하는 양친매성 공중합체와 산화철 나노입자를 포함하는 미셀을 pH 민감성 물질이 포접하는 마이크로스피어.
- 제1항에 있어서, 상기 pH 민감성 물질은 메타크릴산·메틸메타크릴레이트 공중합체, 메타크릴산·에틸아크릴레이트 공중합체, 메틸아크릴레이트·메틸메타크릴레이트·메타크릴산 공중합체, pHEMA(2-히드록시에틸 메타크릴레이트), 폴리아크릴산 및 키토산으로 이루어진 군으로부터 선택되는 것인 마이크로스피어.
- 제1항에 있어서, 상기 친수성 중합체는 메톡시폴리에틸렌글리콜(mPEG), 폴리 비닐 알코올(PVA) 및 셀룰로오스로 이루어진 군으로부터 선택되는 것인 마이크로스피어.
- 삭제
- 제1항에 있어서, 상기 친수성 중합체와 상기 소수성 중합체는 아미드 결합으로 결합되는 것인 마이크로스피어.
- 제1항에 있어서, 상기 마이크로스피어는 소장의 조영을 위해 사용되는 것인 마이크로스피어.
- 제1항에 있어서, 상기 마이크로스피어는 경구용 조영제로 사용되는 것인 마이크로스피어.
- 제1항 내지 제3항 및 제5항 내지 제7항 중 어느 한 항의 마이크로스피어를 포함하는 소장의 조영을 위한 조성물.
- 제8항에 있어서, 상기 조성물은 경구용으로 사용되는 것인 조성물.
- 친수성 중합체와 소수성 중합체로 구성되는 양친매성 공중합체를 형성하는 단계;
상기 양친매성 공중합체 및, 산화철 이온을 발생시키는 화합물을 포함하는 산화철 나노입자 전구체 용액을 혼합하여 미셀을 제조하는 단계; 및
상기 미셀에 pH 민감성 물질을 첨가하여 마이크로스피어를 제조하는 단계를 포함하는, 소장 조영을 위한 마이크로스피어의 제조 방법. - 제10항에 있어서, 상기 양친매성 공중합체와 상기 산화철 나노입자 전구체 용액은 1:0.00001 내지 1:1의 중량비로 혼합되는 것인 마이크로스피어의 제조 방법.
- 제10항에 있어서, 상기 pH 민감성 물질은 유중수형 에멀젼(water in oil emulsion)방법으로 첨가되는 것인 마이크로스피어의 제조 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100024761A KR101057484B1 (ko) | 2010-03-19 | 2010-03-19 | 소장의 조영을 위한 경구용 조영제 |
PCT/KR2010/006628 WO2011115342A1 (ko) | 2010-03-19 | 2010-09-29 | 소장의 조영을 위한 경구용 조영제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100024761A KR101057484B1 (ko) | 2010-03-19 | 2010-03-19 | 소장의 조영을 위한 경구용 조영제 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101057484B1 true KR101057484B1 (ko) | 2011-08-17 |
Family
ID=44650577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100024761A Expired - Fee Related KR101057484B1 (ko) | 2010-03-19 | 2010-03-19 | 소장의 조영을 위한 경구용 조영제 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101057484B1 (ko) |
WO (1) | WO2011115342A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014065513A1 (ko) * | 2012-10-25 | 2014-05-01 | 서강대학교 산학협력단 | 약물을 함유한 나노입자가 결합된 초음파 조영제 및 이의 제조방법 |
KR101419137B1 (ko) * | 2012-12-20 | 2014-07-14 | 가톨릭대학교 산학협력단 | 약물전달을 위한 기체생성 약물전달체 및 이의 제조방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060266982A1 (en) * | 2005-05-27 | 2006-11-30 | Wei-Fang Su | Composite material with electron-donating and electron-accepting property, method for forming the same, and their application |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4428851C2 (de) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
KR100848931B1 (ko) * | 2006-02-24 | 2008-07-29 | (주)에이티젠 | 양친매성 화합물 및 조직 특이적 결합 성분을 이용한지능형 자성 나노복합체 및 이를 포함하는 조영제 |
KR100827292B1 (ko) * | 2006-05-30 | 2008-05-07 | 애니젠 주식회사 | 실리콘-포함 수용성 고분자로 코팅된 나노입자 및 그의조영제로서의 용도 |
WO2009031859A2 (en) * | 2007-09-06 | 2009-03-12 | Anygen Co., Ltd. | Multi-functional complex for imaging and drug delivery |
KR100943043B1 (ko) * | 2008-02-05 | 2010-02-24 | 전북대학교산학협력단 | 산화철 나노입자가 봉입된 수용성 키토산-소수성 리놀레산복합체 자기-조립 나노입자, 이의 제조방법 및 이를포함하는 간질환 진단용 조영제 |
CN102099408B (zh) * | 2008-05-16 | 2015-01-14 | 悉尼大学 | 聚合物微凝胶珠及其制备方法 |
-
2010
- 2010-03-19 KR KR1020100024761A patent/KR101057484B1/ko not_active Expired - Fee Related
- 2010-09-29 WO PCT/KR2010/006628 patent/WO2011115342A1/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060266982A1 (en) * | 2005-05-27 | 2006-11-30 | Wei-Fang Su | Composite material with electron-donating and electron-accepting property, method for forming the same, and their application |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014065513A1 (ko) * | 2012-10-25 | 2014-05-01 | 서강대학교 산학협력단 | 약물을 함유한 나노입자가 결합된 초음파 조영제 및 이의 제조방법 |
KR101419137B1 (ko) * | 2012-12-20 | 2014-07-14 | 가톨릭대학교 산학협력단 | 약물전달을 위한 기체생성 약물전달체 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
WO2011115342A1 (ko) | 2011-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Structure-property relationships in manganese oxide-mesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery | |
Hsu et al. | Silica–F127 nanohybrid-encapsulated manganese oxide nanoparticles for optimized T 1 magnetic resonance relaxivity | |
Amani et al. | Multifunctional magnetic nanoparticles for controlled release of anticancer drug, breast cancer cell targeting, MRI/fluorescence imaging, and anticancer drug delivery | |
Nguyen et al. | Nano-confinement-driven enhanced magnetic relaxivity of SPIONs for targeted tumor bioimaging | |
Liao et al. | Multifunctional Nanoparticles Composed of A Poly (dl‐lactide‐coglycolide) Core and A Paramagnetic Liposome Shell for Simultaneous Magnetic Resonance Imaging and Targeted Therapeutics | |
US11571486B2 (en) | Bilirubin derivative-based diagnostic and therapeutic ultrasound contrast agent | |
Zhang et al. | PLGA protein nanocarriers with tailor-made fluorescence/MRI/PET imaging modalities | |
Yang et al. | Biodegradable yolk-shell microspheres for ultrasound/MR dual-modality imaging and controlled drug delivery | |
KR102254093B1 (ko) | 빌리루빈 유도체 및 금속을 포함하는 입자 | |
WO2012030134A2 (en) | Iron oxide nanocapsules, method of manufacturing the same, and mri contrast agent using the same | |
Liao et al. | Magnetic/gold core–shell hybrid particles for targeting and imaging-guided photothermal cancer therapy | |
Shah et al. | EDTA capped iron oxide nanoparticles magnetic micelles: drug delivery vehicle for treatment of chronic myeloid leukemia and T 1–T 2 dual contrast agent for magnetic resonance imaging | |
KR102026100B1 (ko) | 극미세 산화철 나노입자 기반 자기공명영상 t1 조영제 | |
Biglione et al. | Revealing the NIR-triggered chemotherapy therapeutic window of magnetic and thermoresponsive nanogels | |
Khalkhali et al. | Simultaneous diagnosis and drug delivery by silymarin-loaded magnetic Nanoparticles | |
Mohammadi et al. | pH-sensitive polyacrylic acid/Fe3O4@ SiO2 hydrogel nanocomposite modified with agarose for controlled release of quercetin | |
US10940217B2 (en) | Polyphosphazene delivery system for inorganic nanocrystals | |
KR101057484B1 (ko) | 소장의 조영을 위한 경구용 조영제 | |
Esthar et al. | An effective biodegradable curcumin loaded magnetic microsphere: Applications for drug delivery and cancer treatment | |
KR101352316B1 (ko) | 무기화된 폴리에틸렌 글리콜 함유 양친성 나노입자를 포함하는 약물 전달체 | |
Zhang et al. | The effect of formulation morphology on stimuli-triggered co-delivery of chemotherapeutic and MRI contrast agents | |
Wang et al. | Construction of block copolymers for the coordinated delivery of doxorubicin and magnetite nanocubes | |
WO2019004297A1 (ja) | ナノ粒子、これを含む磁気共鳴イメージング用造影剤及びリガンド化合物 | |
JP5685647B2 (ja) | 酸化鉄ナノカプセル、その製造方法およびそれを含む磁気共鳴画像診断造影剤 | |
Lee | Manganese Ferrite (MnFe₂O₄) based Magnetic Nano-Cluster for T₂ Weighted 3T MR Imaging in Triple-Negative Breast Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20100319 |
|
PA0201 | Request for examination | ||
A302 | Request for accelerated examination | ||
PA0302 | Request for accelerated examination |
Patent event date: 20101008 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20100319 Patent event code: PA03021R01I Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20101206 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110405 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20110801 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20110810 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20110811 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20141006 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20141006 Start annual number: 5 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170706 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20170706 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190110 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20190110 Start annual number: 8 End annual number: 8 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20210521 |